

Press release 16-09-2014

## **WntResearch shares**

Tommy Andersson, CSO, WntResearch has for personal and financial reasons sold a small amount of his shares in WntResearch. After this, Tommy Andersson still has a significant number of shares in WntResearch. It should be stressed that Tommy Andersson does not have any insider information about the ongoing clinical phase I study or on other activities in WntResearch which would influence the share price. The Company's clinical phase I study is running according to the plans and no dose limiting toxicity has been observed.

**For additional information please contact:**

Nils Brünner, VD

E-post: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)/[nbr@sund.ku.dk](mailto:nbr@sund.ku.dk)

Telefon: + 45 2614 4708

**Om WntResearch**

WntResearch AB is a public Company on the AktieTorget in Sweden. WntResearch develops anti-cancer drugs to be used to combat metastatic spread of cancer cells. WntResearch has one drug candidate in clinical phase I study – Foxy-5- and one drug candidate in preclinical development – Box-5. The Company is currently mainly focusing on the development of Foxy-5.